Research map: Comparing Real-Time PCR and Amplicon-Based NGS for Routine EGFR Liquid Biopsy Profiling

Back to the article

Papers in this map

  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma · Tony S.K. Mok · 2009 · 8328 citations · Cited by this paper
  2. Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC) · 2026 · Related
  3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial · Rafael Rosell · 2012 · 5561 citations · Cited by this paper
  4. Inflammatory–Hematological Profiles in Nasopharyngeal Carcinoma and Suspicious Adenoid Hypertrophy: An Exploratory Single-Center Study · 2026 · Related
  5. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer · Jean‐Charles Soria · 2017 · 5482 citations · Cited by this paper
  6. Lactate Clearance as a Prognostic Marker in Severe Trauma: A Retrospective Cohort Study · 2026 · Related
  7. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations · Lecia Van Dam Sequist · 2013 · 3281 citations · Cited by this paper
  8. Head-to-Head 18F-rhPSMA-7.3 and 18F-PSMA-1007 PET/CT in Recurrent Prostate Cancer: Pulmonary and Nodal Uptake as a Diagnostic Challenge · 2026 · Related
  9. Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC · Suresh S. Ramalingam · 2019 · 2942 citations · Cited by this paper
  10. Fractional Flow Reserve Measurement Using Dynamic CT Perfusion Imaging in Patients with Heavy Coronary Calcification and Stent · 2026 · Related
  11. Sotorasib for Lung Cancers with KRAS p.G12C Mutation · Ferdinandos Skoulidis · 2021 · 1874 citations · Cited by this paper
  12. A Genetic Algorithm-Optimized ConvNeXtV2-YOLOv8 Framework for Dental Caries Detection in Panoramic Radiographs · 2026 · Related
  13. Current and future perspectives of liquid biopsies in genomics-driven oncology · Ellen Heitzer · 2018 · 1597 citations · Cited by this paper
  14. A New Era in Early Postoperative OCT: Swept-Source Versus Spectral-Domain in Gas-Filled Eyes · 2026 · Related
  15. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M · Kenneth Stephen Thress · 2015 · 1581 citations · Cited by this paper
  16. Preoperative Glucose–Albumin Ratio and Its Association with Postoperative Outcomes in Critically Ill Adult Burn Patients: A Retrospective Cohort Study of 1119 Patients · 2026 · Related
  17. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer · Alessandro Leonetti · 2019 · 1444 citations · Cited by this paper
  18. Patella Alta on X-Ray and MRI: Diagnostic Agreement and Clinical Correlations · 2026 · Related
  19. Detection and quantification of rare mutations with massively parallel sequencing · Isaac Kinde · 2011 · 1267 citations · Cited by this paper
  20. Disproportionate Subgaleal Hemorrhage in an Infant: Abuse or Bleeding Disorder? · 2026 · Related
  21. Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation · Pasi Antero Janne · 2022 · 1052 citations · Cited by this paper
  22. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial · David Planchard · 2016 · 898 citations · Cited by this paper
  23. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide · Adalberto Miranda‐Filho · 2024 · 872 citations · Cited by this paper
  24. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis · Yuelun Zhang · 2016 · 816 citations · Cited by this paper
  25. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study · Yi-Long Lung Cancer Wu · 2015 · 741 citations · Cited by this paper
  26. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group · Javier Pascual · 2022 · 738 citations · Cited by this paper
  27. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC · David Planchard · 2023 · 732 citations · Cited by this paper
  28. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study · Tony S.K. Mok · 2020 · 711 citations · Cited by this paper
  29. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer · Christian Diego Rolfo · 2021 · 684 citations · Cited by this paper
  30. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors · Neal Ian Lindeman · 2018 · 651 citations · Cited by this paper
  31. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer · Natasha B. Leighl · 2019 · 612 citations · Cited by this paper
  32. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers · Collin Michael Blakely · 2017 · 599 citations · Cited by this paper
  33. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 · Anita T. Shaw · 2019 · 593 citations · Cited by this paper
  34. Targeting the PI3K/Akt/mTOR pathway in non‐small cell lung cancer (NSCLC) · Aaron C. Tan · 2020 · 564 citations · Cited by this paper
  35. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC · Byoung Chul Cho · 2024 · 453 citations · Cited by this paper
  36. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR -Mutant Lung Cancer · Adam Jacob Schoenfeld · 2020 · 411 citations · Cited by this paper
  37. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group · Maria Fernanda Mosele · 2024 · 409 citations · Cited by this paper
  38. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis · David Planchard · 2021 · 284 citations · Cited by this paper
  39. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors · Jana Fassunke · 2018 · 144 citations · Cited by this paper

Source: OpenAlex (CC0)